The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

DrugBank

OCTOBER 4, 2024

Intellectual Property Valuation Valuing intellectual property (IP) assets is a critical component of pharmaceutical M&A, as these assets often represent a significant portion of a company's value. billion, and the notoriously high failure rates in drug development have incentivized these companies to seek external innovation.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Molecule Blog

MARCH 17, 2023

Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Clinical Trials Government 52

DrugBank

MARCH 22, 2024

There are many obstacles that you have to overcome on the road to success in early-stage drug discovery and drug repurposing research. Research is emerging at a never before seen rate, and it is causing challenges for researchers and scientists to not only stay on top of the latest publications, but to validate conflicting information.

Licensing 98

Licensing Licensing Research Clinical Trials 98

The Pharma Data

NOVEMBER 11, 2020

TOKYO & AUSTIN, Texas–( BUSINESS WIRE )– Taiho Pharmaceutical Co., Lung Tx”) announced today an exclusive license agreement of LTI-01 , a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions , for the territory of Japan. “LTI-01

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

PPD

MAY 7, 2024

The JCA starts with the formulation of a defined research question, based on policy questions from member health care systems. Translation of the policy question into a research question through a PICO provides the ability to specify the data requirements and the framework for the assessment.

Regulations 52

Regulations Pharmaceutical Companies International Pharmaceuticals 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Pharmaceutical Companies Clinical Trials 40

The Pharma Data

MARCH 16, 2021

This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

Policy Prescription

MAY 28, 2021

NeedyMeds , a non-profit organization known for providing patients with help in finding pharmaceutical company-sponsored prescription assistance programs and other drug savings options, hosted a webinar about drug importation last year called “ Drug Importation: The topic everyone’s talking about.” Emphasis added).

Pharmacy 52

Pharmacy Licensing Licensing Online Pharmacies 52

The Pharma Data

NOVEMBER 25, 2020

The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As a business executive at IBM Research in New York, Dr Singh led the go-to-market for IBM Watson Genomics Analytics.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

DECEMBER 8, 2020

The company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. About Gubra.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Drug Target Review

FEBRUARY 1, 2024

We were able to license a molecule from a multi-national pharmaceutical company. What do you predict for the future of neuroscience research in the next several years, and Neurvati’s role in this? It’s a great example of how our model works. That molecule had safety data from several hundred patients.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

FEBRUARY 22, 2021

Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox’s trade secrets and grant a license to Evolus to continue to commercialize Jeuveau® in the United States and Nuceiva in all other territories in which Evolus has licensing rights.

Licensing 40

Licensing Licensing Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. After focusing on antimicrobial research for years, Leeds now heads a BD&L effort that builds relationships and collaborations with companies on the West Coast of the US and across all of Canada.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

JANUARY 19, 2021

His research focus is all possible aspects of malignant lymphomas, aiming for the improvement of the quality of life and survival of these patients. The Company’s validated, proprietary F.I.R.S.T To register for the call, please click here. Dr. Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

OCTOBER 6, 2021

Early-stage research suggests potential to prevent and treat all dengue serotypes With no treatments available, dengue infects up to 400 million people each year and the pace of outbreaks is increasing. [1] 1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats.

Virus 52

Virus Clinical Development Science Disease 52

The Pharma Data

JANUARY 26, 2021

The granted patent underlines BioArctic’s commitment in the brain diseases field in general and in Alzheimer’s disease research specifically. The company was founded in 2003 based on innovative research from Uppsala University , Sweden. This information was submitted for publication at 08:00 a.m. About BioArctic AB.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

NOVEMBER 10, 2020

The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. STOCKHOLM , Nov. STOCKHOLM , Nov.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 4, 2021

5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. ” About the License Agreement.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. If you mean using a different contract research organization (CRO) for the different phases of clinical trials – that’s different. A: Working in a pharmaceutical company is the best way to learn this. A: This does not usually happen.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

MARCH 2, 2021

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S.

Vaccine 52

Vaccine Clinical Trials FDA Licensing 52

The Pharma Data

JANUARY 27, 2021

The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 26, 2020

The company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

JANUARY 10, 2021

LA ROCHELLE, France–( BUSINESS WIRE )– Regulatory News: VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its participation in the prestigious ‘J.P.

International 40

International Pharmaceutical Companies Disease Licensing 40

Practical Cheminformatics

DECEMBER 7, 2023

The Medicinal Chemistry Gordon Research Seminar ( GRS ) provides a condensed version of ResMed. It should be noted that not all biotechs skimp on software licenses. Before joining any company, it’s important to know before you go and ask about software resources and budgets. Chem provides a lot of great advice for drug hunters.

Computational Chemistry 86

Computational Chemistry Pharmacokinetics Drugs Pharmaceutical Companies 86

The Pharma Data

JANUARY 25, 2021

At their option, the collaboration with the European affiliate of a global pharmaceutical company has expanded to three active pharmaceutical ingredients (“API”s). The Q-Sphera R&D pipeline has expanded to a net five active projects with all proceeding to plan. Closure of Bilbao Operations.

Licensing 52

Licensing Licensing Production Regulations 52

The Pharma Data

NOVEMBER 5, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced two Phase III trials, DISCOVER-1 and 2 demonstrated Tremfya (guselkumab) improved fatigue in adults with active psoriatic arthritis (PsA). There was a handful of positive clinical trial news reported today. Here’s a look. Janssen’s Tremfya.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). Fox Foundation, the largest non-profit organisation for supporting Parkinson’s research.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

OCTOBER 14, 2020

Astellas and iota previously entered into a Research and Development Agreement in August 2019 (the “R&D Agreement”) to jointly conduct research and development activities associated with iota’s ultrasonic-powered bioelectronic devices (also known as “neural dust”) in a number of indications. and Jose Carmena, Ph.D., About Astellas.

Disease 40

Disease Production Pharmaceuticals Clinical Trials 40

The Pharma Data

JANUARY 5, 2021

director of research programs for the Foundation for Prader-Willi Research, said, “With a focus on individuals with PWS and their caregivers, our mission is to accelerate research and support the development of therapies that will eliminate the challenges of PWS.” Theresa Strong, Ph.D., ” Dr. .”

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

DECEMBER 29, 2020

(NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A., About Chiesi Group.

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Pharma Data

JANUARY 24, 2021

The FTD will significantly accelerate the research, development, and marketing of Toripalimab in the United States. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.

FDA 40

FDA Clinical Trials Trials Treatment 40